Focused On-demand Library for Norrin

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q00604

UPID:

NDP_HUMAN

Alternative names:

Norrie disease protein; X-linked exudative vitreoretinopathy 2 protein

Alternative UPACC:

Q00604; B2R8K6; Q5JYH5

Background:

Norrin, also known as Norrie disease protein and X-linked exudative vitreoretinopathy 2 protein, is pivotal in activating the canonical Wnt signaling pathway through FZD4 and LRP5 coreceptors. It plays a crucial role in retinal vascularization, signaling via beta-catenin stabilization and LEF/TCF-mediated transcriptional programs. Norrin acts alongside TSPAN12 to activate FZD4, indicating a Wnt-independent signaling pathway that also promotes beta-catenin accumulation. Its involvement in neural cell differentiation and proliferation, as well as neuroectodermal cell-cell interaction, underscores its biological significance.

Therapeutic significance:

Norrin's association with Norrie disease, characterized by early childhood blindness and potential mental disorders, and Vitreoretinopathy, exudative 2, highlights its therapeutic significance. Understanding Norrin's role in these diseases could lead to innovative treatments targeting the underlying genetic variants, offering hope for patients suffering from these retinal disorders.